Oppenheimer analyst Christopher Marai out today with his second note this week on Celldex Therapeutics (NASDAQ:CLDX) maintaining an Outperform rating, with a $36 price target, as …
Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Celldex Therapeutics (NASDAQ:CLDX) with a $40 price target, following the company’s third-quarter results, posting EPS …
Oppenheimer analyst Christopher Marai reiterated an Outperform rating on Celldex Therapeutics (NASDAQ:CLDX) with a price target of $36.00, which represents a potential upside …
In a research report released today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Celldex Therapeutics (CLDX) with a $40 price …
In a research report released yesterday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Celldex Therapeutics (CLDX) with a $40 price …
